From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Class III beta-tubulin (TUBB3) is overexpressed in various cancers, including ovarian, lung, breast, and gastric.
• No current clinical drugs specifically target TUBB3, although IDN5390 is an investigational drug that interacts with it.

Purpose of the Study:

• To investigate the pathways responsible for TUBB3 up-regulation.
• To identify molecular mechanisms underlying resistance to cancer therapies.

Main Methods:

• Human genome microarray analysis in IDN5390-resistant A2780 cells.
• Quantitative PCR to assess semaphorin 6A (SEMA6A) and TUBB3 expression.
• Analysis of SEMA6A expression in cells with stable SEMA6A overexpression or silencing.

Main Results:

• Semaphorin 6A (SEMA6A) was down-regulated in cells resistant to IDN5390 and other chemotherapies (cisplatin, topotecan, doxorubicin), but not paclitaxel or gemcitabine.
• Acute IDN5390 treatment reduced SEMA6A levels in drug-sensitive cells.
• TUBB3 expression positively correlated with SEMA6A levels; TUBB3 increased with SEMA6A overexpression and decreased with SEMA6A silencing.
• An 83 kDa form of SEMA6A was found associated with beta-actin in the cytoskeleton.

Conclusions:

• SEMA6A expression is inversely correlated with TUBB3 levels, suggesting a role in regulating TUBB3.
• SEMA6A may have a novel function in the cytoskeleton, influencing tubulin composition and microtubule dynamics.
• Findings provide insights into potential therapeutic strategies targeting TUBB3 and drug resistance mechanisms.